Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07750873 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of CRD-4730 in HFrEF

Study acronym: CALIBRATE-HF
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.
Trial Details
NCT Number NCT07750873
Lead Sponsor Cardurion Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Heart Failure With Reduced Ejection Fraction (HFrEF)
Related terms Heart Failure
Enrollment 525 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov